Accord Healthcare recalls levothyroxine sodium 300 mcg tablets because they are weaker than labeled
The recalled levothyroxine tablets are subpotent, meaning they contain less medicine than the label says, so they may not work as well as intended.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-458-15.
- Company
- Accord Healthcare, INC.
- Hazard
- Subpotent Drug
- Units
- 6432 bottles
- Where sold
- US Nationwide.
- FDA classification
- Class II · Ongoing
- Classified by FDA
- June 30, 2026
- Recall started
- June 8, 2026
- FDA enforcement report
- July 8, 2026
- Identifiers
- Codes: Lot # D2401522, Exp Date: 06/2026.
- FDA recall number: D-0656-2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-458-15.
- Reason for recall
- Subpotent Drug
- Classification
- Class II (Ongoing)
- Distribution
- US Nationwide.
- Quantity
- 6432 bottles
Related recalls
Accord Healthcare recalls levothyroxine sodium tablets because they may be weaker than labeled
The recalled levothyroxine tablets are subpotent, meaning they may contain less of the medicine than the label says, so they may not work as well as intended.
Accord Healthcare recalls levothyroxine sodium tablets 88 mcg over weaker-than-labeled strength
During long term stability testing of the 88 mcg tablets, the amount of active ingredient was found to be below the approved range, so the tablets are subpotent.
Accord Healthcare, INC. · 54,432 bottles
Pfizer recalls Levoxyl 175 mcg levothyroxine sodium tablets over weaker-than-labeled strength
The tablets are subpotent, meaning they are weaker than labeled, after a stability test confirmed an out-of-specification assay result.
Pfizer · 15,949 units
Major Pharmaceuticals recalls levothyroxine sodium tablets because they may be weaker than labeled
The recalled levothyroxine tablets (75 mcg, 88 mcg and 150 mcg strengths) are subpotent, meaning they contain less medicine than the label says.